




1



2



3

What (little) I know about HCM

Feline Hypertrophic Cardiomyopathy: An Update

Jonathan A. Abbott, DVM Vet Clin NA 2010; 40

Genetic basis

Frequent finding in cats – **Most common** myocardial dz diagnosed in cats

Mean age at diagnosis is **6 years**

Many asymptomatic at presentation (30%-50%)

Heterogeneous disease: have some long survival, some develop CHF or thromboembolism, some die suddenly

Some but not all cats with HCM have a **murmur** (1/3 in one study)

Many will develop **LVOTO (SAM)**

Few cases of **LVOTO** without hypertrophy

4

Pathophysiology of HCM

Feline Hypertrophic Cardiomyopathy: An Update

Jonathan A. Abbott, DVM Vet Clin NA 2010; 40

Generally accepted as **diastolic dysfunction**

Delayed ventricular **relaxation** and **diminished compliance**

Higher filling pressures at low to normal volumes

Pulmonary **congestion** or edema

Atrial enlargement

5

Pathophysiology of HCM

Feline Hypertrophic Cardiomyopathy: An Update

Jonathan A. Abbott, DVM Vet Clin NA 2010; 40

Global **systolic** function is commonly **normal** or **hyperdynamic**


LVOTO (or SAM) is a **common, complex, associated** phenomenon

Results from systolic motion of valve leaflets towards septum

It is **dynamic**, as opposed to anatomical (**fixed**) obstructions (stenosis)

This is important, as the **magnitude** of LVOTO may be **manipulated**


6



ACVIM.org

7

LVOTO



Displaced valve leaflets cause mechanical obstruction

The cause is probably multifactorial


Venturi effect initially proposed

Drag forces proposed more recently

Abnormal geometry + chordal laxity

8

LVOTO



SAM impedes LV outflow and **increases wall tension**

Myocardial perfusion abnormalities have been described with SAM

Narrow coronary arteries

Mitral valve regurgitation also observed

9

HCM summary

Poor relaxation (lower filling volume and higher filling pressures)
Reduced ventricular preload

Systolic function **normal** or **hyperdynamic**

SAM

Others

Arrhythmias


Thrombi

Possibly **reduced perfusion**




Cornell Feline Health Center

10



Anesthesia and
hemodynamics

11




General anesthetics

Inhalational agents are **potent vasodilators**
Reduce **afterload**, reflexive **tachycardia**


This also applies to **propofol** or **alfaxalone**
(although they are less vasodilatory)

Does **not** apply to **ketamine** (but may cause
tachycardia too)


12




13



14



15




Ketamine

- Does not vasodilate
- Increases **HR, contractility, and CO**
- Can result in **tachyarrhythmias**

All of the above is predicated on **increasing sympathetic tone**

What could prevent that?
Other drugs

16




Treatment of hypotension during GA

I keep fluid therapy to minimum (2-5 mL/kg/hour).
Fluid therapy is typically **ineffective** for treating hypotension

Hypotension may come from different sources:
Low afterload - very common with GA

Tachycardia – low filling volume

17



Vasopressors vs inotropics


Inotropics (dopamine, dobutamine)

- Both increase contractility and could (potentially) **worsen SAM**
- Likely to **increase HR** and consume **more O₂**
- Dobutamine can **reduce afterload**

Vasopressors (phenylephrine)

- Increases the afterload** improves **BP**, **reduces HR**
- And possibly **reduces** the impact of **SAM**
- At the expense of **CO**

18



19

Dexmedetomidine


Increases afterload (may reduce SAM)

Increases blood pressure (increase in diastolic may help with myocardial perfusion)

Decreases HR (better filling, less tachyarrhythmias)

It's reversible. And analgesic. And not controlled

Sounds pretty good



20

Small Animals

Doppler echocardiographic effects of medetomidine on dynamic left ventricular outflow tract obstruction in cats

Leigh A. Lamont, DVM, MS; Barret J. Balmes, DVM; David D. Sisson, DVM, DACVIM; Kurt A. Grimm, DVM, MS, DACVIM, DACVP; William J. Tranquilli, DVM, MS, DACVIM

Objective—To evaluate the effects of medetomidine on dynamic left ventricular outflow tract (LVOT) obstruction in cats with left ventricular hypertrophy.

Design—Control trial.

Animals—4 domestic shorthair cats with echocardiographic evidence of dynamic LVOT obstruction.

Procedure—Cats were restrained in lateral recumbency, and baseline echocardiographic and Doppler echocardiographic examinations were performed. An ECG was recorded continuously, and blood pressure was measured indirectly with Doppler auscultation. Medetomidine (0.5 µg/kg IV; 1 µg/kg IV) was then administered IM, and examinations were repeated 15 min later.

Results—Significant decreases in heart rate, LVOT velocity, and the LVOT pressure gradient were observed following medetomidine administration. After adjusting for the effects of heart rate by ANCOVAs, there were no significant differences in any other systolic or diastolic indices of left ventricular function.

Conclusions and Clinical Relevance—Results suggest that administration of medetomidine to cats with dynamic LVOT obstruction may result in elimination of outflow tract obstruction; medetomidine may be a suitable sedative and analgesic agent in this subpopulation of cats. (*J Am Vet Med Assoc* 2002;221:1276-1281)

diagnostically that systolic anterior motion is initiated by flow drag forces acting on the protruding mitral valve leaflet and facilitated by the large angle created with hypertrophy of the ventricle between the leaflet and the jet of left ventricular inflow. "Systolic anterior motion of the mitral valve has also been observed in cats with hypertrophic cardiomyopathy and LVOT obstruction" and probably operates through the same mechanism.

Left ventricular outflow tract obstruction increases mitral left ventricular pressure, systemic wall tension, and myocardial work.¹ In addition, coronary perfusion pressure is decreased as aortic diastolic pressure decreases and left ventricular diastolic pressure increases.^{2,3} In human patients, these hemodynamic abnormalities are linked to severe tachycardia associated with hypertension, bradycardia, ventricular tachyarrhythmias, and myocardial ischemia, which can ultimately cause sudden death.⁴ Sudden cardiac death in cats with idiopathic hypertrophic cardiomyopathy has been reported⁵ and is presumably a result of similar types of arrhythmias or ischemia secondary to impaired coronary perfusion.

Many cats with LVOT obstruction do not have any clinically apparent abnormalities and are examined by a veterinarian for a variety of other reasons. In these instances, diagnosis of the underlying cardiac disease may be incidentally. Consequently, it is not uncommon for cats with LVOT obstruction to be sedated or anesthetized without prior diagnosis of their condition. However, even if the condition is identified, the per-

21

Dexmedetomidine is not forbidden (in fact, we use it often)


What could go wrong?

Bradyarrhythmias (sinus b, AV block, AIVR)

Reversal (likely safe if only sedation, different if under GA)

22

Reversal
isn't
magic



23



24



25

To treat or not treat (bradyarrhythmias)?

I do not if BP is acceptable – risk of tachycardia and hypertension

I have developed a tolerance to low HR and benign blocks – this took time

Low HR, blocks, and AIVR that affect BP are treated by **increasing the HR**:

- reduce anesthetics
- reduce opioids
- atropine

26

Sedation

Dexmedetomidine + opioid

Dexmedetomidine + alfaxalone (meaner cats)

Alfaxalone + opioid

I avoid ketamine but know a guy (who knows a guy) who uses it for HCM cats

Effects of intramuscular sedation with alfaxalone and butorphanol on echocardiographic measurements in healthy cats

Thibault Ribas^{1,2}, Isabelle Bublil¹, Stéphane Junot¹, Hugues Beaudreux¹, Benoit Tancou¹, Pauline Gagnaire¹, Jean Luc Cadore¹ and Romain Pariaut¹

Abstract

Objective: The aim of the study was to evaluate the effects of intramuscular (IM) injections of alfaxalone combined with butorphanol on echocardiographic (ECG) measurements in cats. **Animals:** Twelve healthy adult domestic shorthair cats younger than 5 years of age were recruited. All cats that were considered healthy on the basis of physical examination, blood work, amniocentesis, blood pressure measurement and baseline ECG underwent a second ECG under sedation. Cats were sedated with two separate IM injections of butorphanol at 0.2 mg/kg and alfaxalone at 2 mg/kg. ECG variables were analyzed using a linear mixed model, and sedation scores were analyzed using an ordinal mixed logistic model. The significance level was set at $p < 0.05$ and adjusted at $p < 0.007$ for multiple comparisons of the ECG measurements. **Results:** Ten healthy cats were included. Sedation was successful and recovery was smooth and stable for all cats. The mean duration of lateral recumbency was 36.3 ± 4.37 min. Reduction in heart rate following sedation approached statistical significance ($p = 0.002$). The thickness of the interventricular septum, the thickness of the left ventricular free wall, and the left ventricular internal dimensions in diastole and systole were not affected by the sedation. The change in left atrial volume and shortening fraction were statistically significant. Although the peak velocity of early diastolic transmitral flow (E) and late diastolic transmitral flow (A), the peak early diastolic (E/A) ratio, the mitral valve annular velocity, and the peak late diastolic (A) mitral valve annular velocity changed after sedation, the ratios E/A, E/A and E/A were not significantly different after sedation. **Conclusion:** and sedation IM injections of alfaxalone and butorphanol induced rapid, deep and short-acting sedation. The mean differences after sedation were not clinically significant for most echocardiographic measurements.

Journal of Feline Medicine and Surgery
2019, Vol. 23(10) 100-108
© 2019 Taylor & Francis
https://doi.org/10.1080/10899891.2019.1631111
sagepub.com/journalsPermissions.nav
JFM 23(10) 100-108

SAGE

27

Planning GA

Exam, history, and echo (I walk to cardio to discuss)
 If cat is **receiving medication** (typically a beta-blocker), **I do not discontinue** it (except ACEi)
 Discuss increased **risks** of negative events with **owner**

I **always preoxygenate**
 Materials, drugs, and emergency drugs **ready**
 Machine **checked**
(all of that before I give a sedative)

28

Summary of anesthetic management

I try to
 Avoid excessive anesthetic doses (inhalational and propofol)
 Avoid tachycardia
 Avoid substantial drops in afterload (vasodilation)

I favor vasopressors and low heart rates


29

I follow GA from the **sedation** we already discussed


And no matter what the cardiac problem is, the **basics of anesthesia** are always applied
 Airway. Monitoring. Equipment. Contingency plans

Don't get **tunnel vision** and forget the rest

30



31



32
